Czech National Bank Purchases 989 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Czech National Bank grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,442 shares of the biopharmaceutical company’s stock after purchasing an additional 989 shares during the period. Czech National Bank’s holdings in Regeneron Pharmaceuticals were worth $17,735,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Insigneo Advisory Services LLC increased its holdings in Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after buying an additional 13 shares in the last quarter. Guardian Wealth Advisors LLC NC raised its holdings in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 14 shares during the last quarter. Arjuna Capital lifted its holdings in Regeneron Pharmaceuticals by 3.2% in the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 14 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 15 shares during the period. Finally, MCF Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 50.0% during the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Barclays maintained its Buy rating on Regeneron. The reaffirmed bullish view provides support for REGN, particularly after the company’s recent earnings beat, which included revenue growth and earnings per share well above consensus. Barclays Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Intellia Therapeutics reported lower revenue because of reduced Regeneron collaboration revenue. Intellia’s second-quarter revenue declined 46.2%, but the item reflects Intellia’s financial results rather than a newly announced change in Regeneron’s pipeline or partnership strategy. NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
• Negative Sentiment: Several law firms reiterated notices about a pending securities class action against Regeneron. The lawsuit concerns alleged disclosure issues surrounding the failed Phase 3 melanoma trial, which reportedly led to a substantial market-value loss. Investors who purchased REGN shares during the August 1, 2025–May 15, 2026 class period have until September 14, 2026 to seek lead-plaintiff status. The repeated notices add legal and reputational risk but do not indicate a new lawsuit-related financial liability. Regeneron Class Action Lawsuit Deadline Notice

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently weighed in on REGN. TD Cowen increased their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. JPMorgan Chase & Co. reduced their price target on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research report on Monday, May 18th. Truist Financial boosted their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $797.75.

Regeneron Pharmaceuticals Trading Up 1.6%

NASDAQ REGN opened at $784.36 on Friday. The stock has a market cap of $82.92 billion, a P/E ratio of 19.39, a PEG ratio of 1.32 and a beta of 0.22. The company’s fifty day simple moving average is $657.28 and its 200-day simple moving average is $712.33. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the business earned $12.81 EPS. The business’s revenue was up 16.7% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.